Posted by Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, delivered eight presentations and posters highlighting results from its antibiotics portfolio and pipeline will be presented at the Infectious Diseases Society of America IDWeek™ 2018 meeting, held October 3 to 7, 2018 in San Francisco, CA.
This package included three posters on Baxdela, Melita’s SBECD-enabled delafloxacin.
Baxdela® (delafloxacin):
- Poster #2378 (October 6, 2018 from 12:30-1:45pm PT) – Resolution of Signs and Symptoms (S&S) of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) with Delafloxacin (DLX) IV/oral therapy
- Poster #2373 (October 6, 2018 from 12:30-1:45pm PT) – Evaluation of Delafloxacin Activity and Treatment Outcome for Phase 3 Acute Bacterial Skin and Skin Structure Infection Clinical Trial Anaerobic Isolates
- Poster #2377 (October 6, 2018 from 12:30-1:45pm PT) – Outcomes in patients with history of cardiac or vascular disease (CV) during treatment of acute bacterial skin and skin structure infection (ABSSSI) with delafloxacin (DLX) vs vancomycin/aztreonam (VAN/AZ)